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Published by Elsevier Inc.CORRESPONDENCELetters to the Editor
RCarotid Intima-Media
Thickness Progression and
Cardiovascular Disease Risk
Costanzo et al. (1) concluded that slowed progression of carotid
intima-media thickness (CIMT) with drug therapies does not
predict reduced cardiovascular disease (CVD) risk. Unfortunately,
their analytical technique, meta-regression, is not suitable for
evaluating this relationship. The limitations of meta-regression are
well-known (2). Major pitfalls of their study include the following:
1. CIMT is not a standardized technology. Their meta-regression
included studies with different imaging and measurement
techniques. By grouping them, the authors created a null bias.
Furthermore, some laboratories have highly reproducible tech-
niques and excellent quality assurance procedures. Those labo-
ratories have reliably reported strong relationships between
changes in CVD risk factors, changes in CIMT, and CVD risk.
But, some laboratories have poor measurement accuracy and
reproducibility. Because the meta-regression lumped widely
differing methodologies together, it is no surprise that they did
not find a relationship among all the noise from the individual
trials. Adjusting for the year of the study, the authors’ proposed
solution, does not address this problem.
2. Short follow-up duration. CIMT progression studies are ex-
periments that evaluate one biological effect of an interven-
tion—change in carotid atherosclerosis burden (or more pre-
cisely, change in wall thickness, a measure of arterial injury).
CIMT progression studies are performed to obtain information
about the effect of an intervention on the arterial wall in a
shorter time period than usually is needed to observe differences
in CVD event rates. The short-term events analyzed by the
authors may not reflect the anatomic substrate measured by
CIMT testing, because short-term events are more related to
inflammation and thrombosis than atherosclerosis burden. Pro-
ponents of CIMT imaging as a research tool do not claim that
CIMT changes perfectly reflect CVD risk, especially in the
short term. Their analysis attacks a red herring and faults a
technique for not predicting events that are not mediated by
what it measures. Indeed, the Cholesterol Lowering Athero-
sclerosis Study showed a significant relationship between
CIMT changes and lipid treatment after 2 years, but the
relationships between changes in lipids, CIMT, and CVD
events took many more years to be identified (3,4). The studies
analyzed by Costanzo et al. (1) were, for the most part, only 1
to 2 years in duration.
. The meta-regression was performed on summary data, not data
from individual study participants, and there were a lot of
missing data—especially important considerations given the
small number of CVD events they analyzed relative to the large
number of covariates and studies in their models.No surrogate is perfect, but the vast majority of interventions that
reduce CIMT progression also reduce CVD events. Exceptions
include small, poorly conducted studies or interventions where the
beneficial effect on CIMT was observed in different individuals
than those with increased CVD risk (i.e., hormone replacement
therapy). The limitations of meta-regression, short follow-up
duration, and data limitations explain why the authors did not
observe a relationship between CIMT changes and CVD events. It
is noteworthy that another analysis that focused on high-quality
CIMT studies of statins came to a different conclusion (5).
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Carotid Intima-Media Thickness
as a Surrogate Endpoint
We read with great interest the recently published meta-analysis by
Costanzo et al. (1) investigating whether changes in carotid
intima-media thickness (CIMT) affect major cardiovascular end-
points, including cardiovascular-related and all-cause mortality.
The study was carefully executed and reported that changes in
CIMT in response to drug therapy do not translate into changes in
major cardiovascular events. The analysis adds to the growing
understanding that although surrogate endpoints such as CIMT at
baseline may be correlated with clinical outcomes, changes in these
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predict future clinical events (2,3).
However, we would highlight one potential drawback in the
methodology the investigators used—namely that examining the
relationship between changes in CIMT and outcomes with death
included as a primary endpoint is limiting, given that patients who
died during follow-up cannot undergo full serial assessments of
CIMT to calculate a “change.”
We recently performed a similar meta-regression analysis,
looking at 28 trials of novel cardiovascular therapies to see whether
changes in CIMT that result from these therapies are correlated
with nonfatal myocardial infarction (MI) (4). We chose to focus
our primary analysis on nonfatal MI, excluding the endpoint of
death given the reason described above. Our findings raised similar
concerns that changes in CIMT do not consistently predict
cardiovascular events. For example, we found that for each 0.01
mm per year smaller rate of change in CIMT, the odds ratio for
MI was 0.82 (95% confidence interval: 0.69 to 0.96; p  0.018),
but that no significant relationship between mean change in
CIMT and nonfatal MI was noted in randomized controlled trials
evaluating statin therapy or those with high CIMTs at baseline
(p  0.20 in both instances).
The results of this meta-analysis as well as others, although
provocative, must be interpreted cautiously. Overall, we agree with
the authors that larger clinical trials evaluating patient outcomes
generally are needed to evaluate new drug therapy.
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Reply
We write this letter to clarify some issues that have arisen
regarding our study (1). The purpose of our meta-analysis was
mostly driven by the fact that it has been claimed that interventions
that reduce intima-media thickness (IMT) progression also reduce
cardiovascular events. However, although studies that have shown
a relationship between a high IMT and increased risk of cardio-
vascular events do exist (2–4), there is no study that has ever beenpowered and published to show such a relationship. IMT prog-
nostic value has always relied on its relationship with other proven
surrogate endpoints and never with cardiovascular events. The only
study that is often quoted to show a putative relationship between
IMT changes and cardiovascular risk is the review of Espeland et
al. (2). However, it should be stated that, technically, the Espeland
et al. study (2) merely incorporated the addition of change in
carotid IMT as a covariate in a regression model of a meta-analysis
of some statin trials. In particular, they showed that the change in
carotid IMT raised the summary odds ratio of developing a
cardiovascular event on statin therapy from 0.48 to 0.64. In
addition, they included few studies and only those that directly
compared statin therapy with placebo. Therefore, this study cannot
be quoted as clear evidence of a significant relationship between
change in carotid IMT and cardiovascular risk.
Technical aspects concerning the reproducibility of serial intra-
individual changes and lack of standardization of IMT measure-
ments are crucial in understanding the role of this tool in
cardiovascular risk assessment. Despite the fact that carotid IMT
measurements are prone to generate variability in follow-up
studies, in controlled clinical trials, measurement variability has
been decreasing due to technical improvements, standardization,
and training (5). Nevertheless, we could not find any significant
influence of the year of publication. Furthermore, in our meta-
analysis, some source of variability could also have come from the
inclusion of studies with different imaging protocols. However, we
substantially identified 2 major groups: multicenter trials in which
images were handled and IMT measurements recorded off-line in
a core ultrasound laboratory. However, after performing a sensi-
tivity analysis by excluding studies that did not measure IMT in a
central core laboratory, our results again did not significantly
change.
The short follow-up of studies included in our meta-analysis
may be used to justify the lack of association between IMT changes
and cardiovascular risk; however, it becomes troublesome then to
explain why short-term changes in low-density lipoprotein do
predict cardiovascular risk. Thus, although we recognize that IMT
changes perhaps may predict long-term cardiovascular risk, they do
not perform as low-density lipoprotein changes in the short term,
as we have shown in our paper.
Finally, we would like to point out that, as for all meta-analyses,
particularly for those not based on an individual dataset, findings
need to be interpreted with caution and are intended to be
hypothesis-generating. Nonetheless, we believe that the conclusion
from our study can help achieve a better understanding of clinical
trials having IMT as endpoint and the planning of future studies.
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